Monash IVF Group Limited provided revenue guidance for the second half of 2022. Notwithstanding the impact in January 2022 and subject to any further adverse impact from the ongoing Pandemic, the Company remains confident revenue can continue to grow.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 AUD | -1.48% | -2.92% | +2.31% |
04-30 | Wilsons Upgrades Monash IVF to Overweight from Market-Weight, Price Target is AU$1.58 | MT |
04-12 | RBC Capital Markets Starts Monash IVF Group at New Sector Perform, Price Target is AU$1.50 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.31% | 347M | |
+26.37% | 88.08B | |
-24.20% | 75.32B | |
+3.45% | 28.19B | |
+7.05% | 17.78B | |
-13.23% | 16.64B | |
+0.44% | 15.64B | |
+79.93% | 13.81B | |
-26.67% | 13.01B | |
+23.42% | 12.43B |
- Stock Market
- Equities
- MVF Stock
- News Monash IVF Group Limited
- Monash IVF Group Limited Provides Revenue Guidance for the Second Half of 2022